Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Oruka Therapeutics (Nasdaq: ORKA) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. Oruka's presentation is scheduled for Thursday, January 15, 2026 at 9:00 AM PT. A live webcast and replay will be available on the company's investor events website.
The company is a clinical-stage biotechnology firm developing novel biologics for chronic skin diseases including plaque psoriasis. Investors can access the webcast and replay via Oruka's investor events page.
Details
News Market Reaction – ORKA
On Jan 6, the day this news came out, ORKA closed 0.97% below the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference dates
- January 12–15, 2026
- 44th Annual J.P. Morgan Healthcare Conference schedule
- Company presentation date
- January 15, 2026
- Scheduled Oruka presentation at J.P. Morgan conference
- Presentation time
- 9:00 AM PT
- Oruka J.P. Morgan Healthcare Conference session time
Historical Context
-
Director resignation and appointment of Christopher Martin to board roles.
-
Q3 2025 results with strong cash position and clinical progress timelines.
-
Multiple November 2025 investor conference presentations on pipeline programs.
-
$180M PIPE financing to fund R&D, corporate expenses, and working capital.
-
Positive interim Phase 1 results for ORKA-001 in plaque psoriasis.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biologics medical
plaque psoriasis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026.
Presentation Details
Date: Thursday, January 15th, 2026
Time: 9:00 AM PT
A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.